Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
By Wenhui Li, M. J. Moore, N. Vasilieva, J. Sui, S. Wong, M. Berne, M. Somasundaran, J. Sullivan, K. Luzuriaga, T. Greenough and 2 more. 2003
3,254 citations recorded by the source corpus.
Spike (S) proteins of coronaviruses, including the coronavirus that causes severe acute respiratory syndrome (SARS), associate with cellular receptors to mediate infection of their target cells. Here we identify a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), isolated from SARS coronavirus (SARS-CoV)-permissive Vero E6 cells, that efficiently binds the S1 domain of the SARS-CoV S protein. We found that a soluble form of ACE2, but not of the related enzyme ACE1, blocked association of the S1 domain with Vero E6 cells. 293T cells transfected with ACE2, but not those transfected with human immunodeficiency virus-1 receptors, formed multinucleated syncytia with cells expressing S protein. Furthermore, SARS-CoV replicated efficiently on ACE2-transfected but not mock-transfected 293T cells. Finally, anti-ACE2 but not anti-ACE1 antibody blocked viral replication on Vero E6 cells. Together our data indicate that ACE2 is a functional receptor for SARS-CoV.
Subfields: Animal Science and Zoology, Infectious Diseases
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Animal Science and Zoology
In Infectious Diseases
- Fang Li
- D. Veesler
- Ralph S. Baric
- A. Walls
- M. A. Tortorici
- Rachel L. Graham
- Andrew G. Harrison
- Tao Lin
Citations in the corpus
- Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “Both SARS-CoV-2 S and SARS-CoV S bind to angiotensin-converting enzyme 2 (ACE2), which serves as entry receptor (Hoffmann et al., 2020; Letko et al., 2020; Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020; Zhou et al., 2020c).”
- The Evolution and Emergence of RNA Viruses (2009, background): “2005), it is unclear whether this refl ects adaptation to facilitate transmission in the new host species, via utilization of the angiotensin-converting enzyme 2 (ACE2) and CD209L receptors (Li et al. 2003; Jeffers et al. 2004), or selection for immune escape.”
- COVID-19 and diabetes: Knowledge in progress (2020, neutral): “[51] Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al.”
- Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein (2020, methodology): “SARSCoV recognizes its entry receptor hACE2 at the surface of type II pneumocytes using S, which shares 75% overall amino acid sequence identity with SARS-CoV-2 S and 50% identity within their receptor-binding motifs (RBMs) (Li et al., 2005a; Li et al., 2003; Li et al., 2005c; Wan et al., 2020).”
- Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System (2020, background): “Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor.”
- Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC (2013, background): “Yet the use of peptidases by coronaviruses may be more related to their abundant presence on epithelial and endothelial tissues-the primary tissues of coronavirus infection-rather than to their proteolytic activity, which in the case of APN and ACE2 appeared not to be critical for infection 12, 13 .”
- Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion (2020, positive): “…the S230 crystal structure in the cryo-EM map indicated that CDRH2, CDRH3, CDRL1, and CDRL3 contact the B domain (Figures 5A and 5B), which also mediates 1030 Cell 176, 1026–1039, February 21, 2019 binding to human angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor (Li et al., 2003).”
- The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China (2020, neutral): “Even though there are high similarities between SARS-CoV-2 S and RaTG13 S, there are two distinct differences: one is an "RRAR" furin recognition site formed by an insertion residues in the S1/S2 protease cleavage site in SARS-CoV-2, rather than the single Arginine in SARS-CoV [97] [98] [99] [100] [”
- The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade (2020, background): “Among them, 8 residues are strictly conserved in 2019-nCoV, supporting the hypothesis that ACE2 is also the receptor of the newly emerged nCoV (Wan et al., 2020).”
- Predicting linear B-cell epitopes using string kernels (2008, positive): “The S1 domain is responsible for binding to receptors on target cells (Li et al., 2003) and the S2 domain contributes to the subsequence fusion between viral envelope and cellular membrane (Beniac et al.”
- Potential interventions for novel coronavirus in China: A systematic review (2020, background): “In addition, ACE2 is also a functional receptor of SARS‐CoV and it mediates virus entry into the cell through binding with spike (S) protein.(85,86) The S protein of SARS‐CoV is a type I surface glycoprotein and is responsible”
- Molecular immune pathogenesis and diagnosis of COVID-19 (2020, positive): “Several groups of scientists in China have all discovered that SARS-CoV-2, just like SARS-CoV, requires the angiotensinconverting enzyme 2 (ACE2) [1] as a receptor to enter cells [10].”
- Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding (2020, positive): “…and SARS-CoV-2 is the human cell-surface protein angiotensin converting enzyme 2 (ACE2), and the receptor binding domain (RBD) of spike from both these viruses binds ACE2 with high affinity (Hoffmann et al., 2020; Letko et al., 2020; Li et al., 2003; Walls et al., 2020; Wrapp et al., 2020a).”